Postherpetic Neuralgia - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: P70C924ADFAEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Postherpetic Neuralgia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Postherpetic Neuralgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Postherpetic Neuralgia Understanding

The DelveInsight Postherpetic Neuralgia epidemiology report gives a thorough understanding of the Postherpetic Neuralgia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Postherpetic Neuralgia in the US, Europe, and Japan. The report covers the detailed information of the Postherpetic Neuralgia epidemiology scenario in seven major countries (US, EU5, and Japan).

Postherpetic Neuralgia Epidemiology Perspective by DelveInsight

The Postherpetic Neuralgia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Postherpetic Neuralgia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Postherpetic Neuralgia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Postherpetic Neuralgia Detailed Epidemiology Segmentation

The Postherpetic Neuralgia epidemiology covered in the report provides historical as well as forecasted Postherpetic Neuralgia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Postherpetic Neuralgia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Postherpetic Neuralgia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Postherpetic Neuralgia Epidemiology Report and Model provide an overview of the global trends of Postherpetic Neuralgia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Postherpetic Neuralgia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Postherpetic Neuralgia
• The report provides the segmentation of the Postherpetic Neuralgia epidemiology

Report Highlights

• 11-year Forecast of Postherpetic Neuralgia epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Postherpetic Neuralgia
• Cases of Postherpetic Neuralgia by Mutation Types
• Postherpetic Neuralgia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Postherpetic Neuralgia?
• What are the key findings pertaining to the Postherpetic Neuralgia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Postherpetic Neuralgia across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Postherpetic Neuralgia?
• What are the currently available treatments of Postherpetic Neuralgia?

Reasons to buy

The Postherpetic Neuralgia Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Postherpetic Neuralgia market
• Quantify patient populations in the global Postherpetic Neuralgia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Postherpetic Neuralgia therapeutics in each of the markets covered
• Understand the magnitude of Postherpetic Neuralgia population by its epidemiology
• The Postherpetic Neuralgia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF POSTHERPETIC NEURALGIA

3. POSTHERPETIC NEURALGIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Postherpetic Neuralgia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Postherpetic Neuralgia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Postherpetic Neuralgia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Postherpetic Neuralgia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Postherpetic Neuralgia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Postherpetic Neuralgia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Postherpetic Neuralgia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Postherpetic Neuralgia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Postherpetic Neuralgia Treatment and Management
6.2. Postherpetic Neuralgia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Postherpetic Neuralgia Epidemiology in 7MM (2019-2032)
Table 2: Postherpetic Neuralgia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Postherpetic Neuralgia Epidemiology in the United States (2019-2032)
Table 4: Postherpetic Neuralgia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Postherpetic Neuralgia Epidemiology in Germany (2019-2032)
Table 6: Postherpetic Neuralgia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Postherpetic Neuralgia Epidemiology in France (2019-2032)
Table 8: Postherpetic Neuralgia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Postherpetic Neuralgia Epidemiology in Italy (2019-2032)
Table 10: Postherpetic Neuralgia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Postherpetic Neuralgia Epidemiology in Spain (2019-2032)
Table 12: Postherpetic Neuralgia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Postherpetic Neuralgia Epidemiology in the United Kingdom (2019-2032)
Table 14: Postherpetic Neuralgia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Postherpetic Neuralgia Epidemiology in Japan (2019-2032)
Table 16: Postherpetic Neuralgia Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Postherpetic Neuralgia Epidemiology in 7MM (2019-2032)
Figure 2 Postherpetic Neuralgia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Postherpetic Neuralgia Epidemiology in the United States (2019-2032)
Figure 4 Postherpetic Neuralgia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Postherpetic Neuralgia Epidemiology in Germany (2019-2032)
Figure 6 Postherpetic Neuralgia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Postherpetic Neuralgia Epidemiology in France (2019-2032)
Figure 8 Postherpetic Neuralgia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Postherpetic Neuralgia Epidemiology in Italy (2019-2032)
Figure 10 Postherpetic Neuralgia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Postherpetic Neuralgia Epidemiology in Spain (2019-2032)
Figure 12 Postherpetic Neuralgia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Postherpetic Neuralgia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Postherpetic Neuralgia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Postherpetic Neuralgia Epidemiology in Japan (2019-2032)
Figure 16 Postherpetic Neuralgia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report